Author

Brian G. Feagan

EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: 104-WEEK RESULTS FROM A PHASE 2 RANDOMISED CONTROLLED TRIAL
EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: 104-WEEK RESULTS FROM A PHASE 2 RANDOMISED CONTROLLED TRIAL

Brian G. Feagan  et al.

USE OF FAECAL CALPROTECTIN AS A PROGNOSTIC MARKER OF RESPONSE TO TREATMENT WITH FILGOTINIB: POST HOC ANALYSIS FROM THE SELECTION STUDY
USE OF FAECAL CALPROTECTIN AS A PROGNOSTIC MARKER OF RESPONSE TO TREATMENT WITH FILGOTINIB: POST HOC ANALYSIS FROM THE SELECTION STUDY

Brian G. Feagan  et al.

RELATIVE ASSOCIATION OF BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT OR BOWEL URGENCY REMISSION VS STOOL FREQUENCY REMISSION AND RECTAL BLEEDING REMISSION WITH IMPROVEMENT IN IBDQ SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
RELATIVE ASSOCIATION OF BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT OR BOWEL URGENCY REMISSION VS STOOL FREQUENCY REMISSION AND RECTAL BLEEDING REMISSION WITH IMPROVEMENT IN IBDQ SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Brian G. Feagan  et al.

OZANIMOD AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY
OZANIMOD AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY

Brian G. Feagan  et al.

ACHIEVEMENT OF STRINGENT EFFICACY ENDPOINTS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE TREATED WITH UPADACITINIB
ACHIEVEMENT OF STRINGENT EFFICACY ENDPOINTS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE TREATED WITH UPADACITINIB

Brian G. Feagan  et al.

MIRIKIZUMAB IMPROVES WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE SCORES IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAINTENANCE STUDIES
MIRIKIZUMAB IMPROVES WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE SCORES IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAINTENANCE STUDIES

Brian G. Feagan  et al.

MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE SCORES IN PARTICIPANTS OF THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAIN
MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE SCORES IN PARTICIPANTS OF THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAIN

Brian G. Feagan  et al.

ASSOCIATION OF NONSWITCHED MEMORY B-CELL (MBC) LEVELS WITH OZANIMOD (OZA) EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE (CD): RESULTS FROM THE PHASE 2 STEPSTONE STUDY
ASSOCIATION OF NONSWITCHED MEMORY B-CELL (MBC) LEVELS WITH OZANIMOD (OZA) EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE (CD): RESULTS FROM THE PHASE 2 STEPSTONE STUDY

Brian G. Feagan  et al.

EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY
EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY

Brian G. Feagan  et al.

THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 DEMONSTRATES RAPID SYMPTOMATIC AND BIOMARKERS IMPROVEMENT IN ULCERATIVE COLITIS: RESULTS IN A PHASE 1B STUDY
THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 DEMONSTRATES RAPID SYMPTOMATIC AND BIOMARKERS IMPROVEMENT IN ULCERATIVE COLITIS: RESULTS IN A PHASE 1B STUDY

Brian G. Feagan  et al.

ASSESSMENT OF COMPOSITE ENDPOINTS COMPRISING SYMPTOMATIC, HISTOLOGIC, ENDOSCOPIC, AND MOLECULAR IMPROVEMENT IN A PHASE 1B STUDY OF GB004, A GUT-TARGETED, HYPOXIA-INDUCIBLE FACTOR (HIF)-1? STABILIZER, IN MILD-TO-MODERATE ULCERATIVE COLITIS
ASSESSMENT OF COMPOSITE ENDPOINTS COMPRISING SYMPTOMATIC, HISTOLOGIC, ENDOSCOPIC, AND MOLECULAR IMPROVEMENT IN A PHASE 1B STUDY OF GB004, A GUT-TARGETED, HYPOXIA-INDUCIBLE FACTOR (HIF)-1? STABILIZER, IN MILD-TO-MODERATE ULCERATIVE COLITIS

Brian G. Feagan  et al.

THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY

Brian G. Feagan  et al.

REAL-WORLD EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A POOLED MULTICENTRE OBSERVATIONAL COHORT ANALYSIS OF CLINICAL AND MODELED PHARMACOLOGICAL DATA
REAL-WORLD EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A POOLED MULTICENTRE OBSERVATIONAL COHORT ANALYSIS OF CLINICAL AND MODELED PHARMACOLOGICAL DATA

Brian G. Feagan  et al.

EFFECTS OF OZANIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: FLOW CYTOMETRY RESULTS FROM THE STEPSTONE PHASE 2 STUDY
EFFECTS OF OZANIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: FLOW CYTOMETRY RESULTS FROM THE STEPSTONE PHASE 2 STUDY

Brian G. Feagan  et al.

EFFICACY AND SAFETY OF GUSELKUMAB FOR CROHN’S DISEASE THROUGH 3 YEARS: GALAXI-1 LONG-TERM EXTENSION
EFFICACY AND SAFETY OF GUSELKUMAB FOR CROHN’S DISEASE THROUGH 3 YEARS: GALAXI-1 LONG-TERM EXTENSION

Brian G. Feagan  et al.

MAINTENANCE OF WEEK 12 RESPONSES THROUGH WEEK 52 WITH ETRASIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC 52 TRIAL
MAINTENANCE OF WEEK 12 RESPONSES THROUGH WEEK 52 WITH ETRASIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC 52 TRIAL

Brian G. Feagan  et al.

​ENDOSCOPIC SCORING INDICES FOR ASSESSING DISEASE SEVERITY IN FAMILIAL ADENOMATOUS POLYPOSIS: A SYSTEMATIC REVIEW
​ENDOSCOPIC SCORING INDICES FOR ASSESSING DISEASE SEVERITY IN FAMILIAL ADENOMATOUS POLYPOSIS: A SYSTEMATIC REVIEW

Brian G. Feagan  et al.

IMPACT OF MIRIKIZUMAB THERAPY ON HISTOLOGIC MEASURES OF INTESTINAL INFLAMMATION IN A PHASE 2 STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
IMPACT OF MIRIKIZUMAB THERAPY ON HISTOLOGIC MEASURES OF INTESTINAL INFLAMMATION IN A PHASE 2 STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Brian G. Feagan  et al.

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES
AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Brian G. Feagan  et al.

ASSOCIATION OF HISTOLOGIC MEASUREMENT WITH ENDOSCOPIC OUTCOMES AFTER ONE YEAR OF TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE
ASSOCIATION OF HISTOLOGIC MEASUREMENT WITH ENDOSCOPIC OUTCOMES AFTER ONE YEAR OF TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE

Brian G. Feagan  et al.

Item 21 - 40 / 79
1
2
3 4